Increased TIL Levels Associated With Better Outcomes in Patients With HER2-Positive Breast Cancer

A higher quantity of stromal tumor-infiltrating lymphocytes (TILs) was associated with better overall survival in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo, along with trastuzumab and docetaxel, according to a new study.

 Cancer Network